751348
Last Update Posted: 2018-06-08
Recruiting has ended
All Genders accepted | 11 months-24 months |
475 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
This Phase 3b study is being conducted for the purpose of registration of the GSK208136 vaccine in Korea.
Eligibility
Relevant conditions:
Measles
Varicella
Mumps
Rubella
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov